Solid Biosciences Inc 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Registrant’s telephone number, including area code: (617)337-4680 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of October 29, 2025, the registrant had77,910,239shares of common stock, $0.001 par value per share, outstanding. SOLID BIOSCIENCES INC.TABLE OF CONTENTS CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA PART I.FINANCIAL INFORMATION3Item 1.Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets at September 30, 2025 and December 31, 20243Condensed Consolidated Statements of Operations for the three and nine months ended September 30,2025 and 20244Condensed Consolidated Statements of Comprehensive Loss for the three and nine months endedSeptember 30, 2025 and 20245Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine monthsended September 30, 2025 and 20246Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and20248Notes to the Condensed Consolidated Financial Statements10Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk30Item 4.Controls and Procedures30 PART II.OTHER INFORMATIONItem 1.Legal Proceedings 32Item 1A.Risk Factors32Item 2.Unregistered Sales of Equity Securities and Use of Proceeds86Item 5.Other Information86Item 6.Exhibits87 SIGNATURES CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q includes forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believe,” “estimate,”“project,” “anticipate,” “expect,” “seek,” “predict,” “aim,” “continue,” “possible,” “intend,” “may,” “might,” “will,” “could,”“would” or “should” or, in each case, their negative, or other variations or comparable terminology. These forward-lookingstatements include all matters that are not historical facts. They appear in a number of places throughout this Quarterly Report onForm 10-Q. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based uponmany detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict theimpact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Allforward-looking statements are based upon information available to us on the date of this Quarterly Report on Form 10-Q. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: •the timing, progress, design and results of ongoing and planned preclinical studies and clinical trials for ourneuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates;•our ability to establish or maintain collaborations or strategic relationships;•our ability to obtain and maintain U.S. and foreign regulatory approval of our neuromuscular (e.g., SGT-003, SGT-212),cardiac (e.g., SGT